The AKR1B1 Knockout HAP1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human near-haploid fibroblastoid cell line. This product consists of a heterogeneous pool of cells carrying targeted disruptions in the AKR1B1 gene, resulting in loss of functional AKR1B1 (aldose reductase) protein expression. The polyclonal knockout approach provides a robust loss-of-function model without the selective pressure or genetic drift that can accompany single-cell clonal expansion, making it suitable for population-level studies of AKR1B1-dependent processes. The CRISPR/Cas9-mediated gene disruption enables straightforward interrogation of aldose reductase biology across a range of experimental paradigms.
The near-haploid HAP1 cell line is a fibroblastoid derivative of the KBM-7 chronic myeloid leukemia line from a human male. Its haploid genome facilitates gene editing and functional genomics, as a single targeting event yields a null phenotype. HAP1 cells are widely used in genetic screens and signaling studies. The high editing efficiency in this background ensures a polyclonal AKR1B1 knockout pool with minimal wild-type contamination, suitable for robust loss-of-function experiments.
AKR1B1 encodes aldose reductase, a NADPH-dependent aldo-keto reductase that catalyzes the reduction of glucose to sorbitol, the first step of the polyol pathway. This enzyme also participates in detoxification of reactive aldehydes such as methylglyoxal and 4-hydroxynonenal. Under hyperglycemic conditions, AKR1B1 activity is upregulated by osmotic stress and transcription factors NFAT5/TonEBP and AP-1, leading to sorbitol accumulation, NADPH depletion, and fructose production. The resulting osmotic and oxidative stress activates PKC and NF-kB signaling, promotes advanced glycation end-product (AGE) formation, and contributes to vascular and neuronal damage. AKR1B1 functionally interacts with sorbitol dehydrogenase, which converts sorbitol to fructose, linking polyol metabolism to broader metabolic networks.
In the HAP1 near-haploid background, AKR1B1 knockout abolishes glucose-derived sorbitol synthesis, enabling dissection of the polyol pathway’s role in cellular phenotypes. This model is valuable for studying diabetic complications like retinopathy, neuropathy, and nephropathy, and for examining detoxification and metabolic reprogramming in cancer. The polyclonal pool provides a practical balance between knockout efficiency and assessment of population-level responses in high-throughput formats.
Research applications include screening of aldose reductase inhibitors (e.g., epalrestat) via dose-response assays and measuring sorbitol accumulation or NADPH oxidation under high-glucose challenge. The knockout cells can be used to quantify reactive oxygen species (ROS) using DCFH-DA, assess cell viability under osmotic or oxidative stress, and perform immunoblotting or RT-qPCR for downstream targets such as PKC and NF-kB. This model also supports functional genomics studies of aldehyde detoxification and metabolic stress responses. For further details or to discuss custom applications, please contact Ascent Research.
